




>>Entry Name: Milrinone, BAN, INN, USAN

Synonym(s): 1,6-Dihydro-2-methyl-6-oxo[3,4'-bipyridine]-5-carbonitrile, 9CI. 1,2-Dihydro-6-methyl-2-oxo-5-(4-pyridinyl)nicotinonitrile. 5-Cyano-2-methyl[3,4'-bipyridine]-6(1*H*)-one. Corotrope. Primacor. Win 47 203-2. YM 018



CAS Registry Number: 78415-72-2

Related CAS Registry Numbers(s): 100286-97-3

Molecular Formula: C₁₂H₉N₃O

Molecular Weight: 211.223

Accurate Mass: 211.074562

Percentage Composition: C 68.24%; H 4.29%; N 19.89%; O 7.57%

Use/Importance: Phosphodiesterase (type III) inhibitor with positive inotropic and vasodilatory activity. Inotropic agent. Used in treatment of congestive heart failure

Physical Description: Cryst. (DMF aq.)

Development Status: Launched 1989

Melting Point: Mp 300°

Calculated Log P Data: Log P 0.26 (calc)

Other Data: Approx. 20-50 times more potent than Amrinone [DLH33-Y](#)

Hazard & Toxicity: LD₅₀ (rat, orl) 91 mg/kg. LD₅₀ (rat, ivn) 73 mg/kg

Sigma: M4659

References:

- U.S. Pat.*, 1981, *Sterling Drug*, 4 264 612; *CA*, **95**, 62011z, (*synth, pharmacol*)
Alousi, A.A. *et al.*, *J. Cardiovasc. Pharmacol.*, 1983, **5**, 792, (*pharmacol*)
Edelson, J. *et al.*, *J. Chromatogr.*, 1983, **276**, 456, (*hplc*)
Cody, V., *Acta Cryst. C*, 1987, **43**, 1325, (*cryst struct*)
Young, R.A. *et al.*, *Drugs*, 1988, **36**, 158, (*rev*)
Shiao, M.-J. *et al.*, *Heterocycles*, 1990, **31**, 523, (*synth, bibl*)
Colucci, W.S. *et al.*, *J. Am. Coll. Cardiol., Suppl. A*, 1993, **22**, 113A, (*clin trial*)
Wojtczak, A. *et al.*, *J. Biol. Chem.*, 1993, **268**, 6202, (*transthyretin-milrinone complex*)
Martindale, The Extra Pharmacopoeia, 30th edn., *Pharmaceutical Press*, 1993, 672